Recent Articles

May 31, 2016 4:03 pm
Ryan Bushey, Digital Editor
This disease is a potentially deadly disorder that can cause a build-up of fat-like substances notably in the kidneys.
May 31, 2016 9:32 am
Ryan Bushey, Digital Editor
Immunotherapies for treating patients with advanced non-small cell lung cancer will be the first part of this project.
May 25, 2016 2:00 pm
Alexandria Annis, Immunology Analyst, GlobalData
In terms of the potential competition CCX168 may face in the AAV market, GlobalData expects that the drug will hold an advantage over several competitors due to attractive pricing.
May 25, 2016 1:00 pm
Seth Augenstein, Digital Reporter
The erroneous tests could have led to thousands of misdirected health-care decisions over those two years.
May 24, 2016 3:18 pm
Ryan Bushey, Digital Editor
Joseph Papa shed on light on the potential strategy for reducing the drug maker's debt load.
May 24, 2016 11:39 am
Maxime Bourgognon, PharmD, Oncology and Hematology Analyst, GlobalData
Combination approaches have the potential to generate twice as many sales in the recurrent RCC market.
May 24, 2016 10:03 am
Ryan Bushey, Digital Editor
An FDA advisory panel is meeting Wednesday to decide if this drug should be recommended for approval in the U.S. 
May 23, 2016 9:07 am
Ryan Bushey, Digital Editor
This drug is projected to be an important source of revenue for Novo Nordisk.
May 19, 2016 9:12 am
Bo Kowalczyk, M.S, MBA, Vice President of Business Development, AIT Bioscience
Over the past decade, new strategies in peptide design have launched a wave of peptide therapeutics. Currently, there are approximately 140 peptide therapeutics in clinical development with over 500 in preclinical development, and the commercial market for novel innovative peptide therapeutics is expected to increase to $17.0 billion by 2018.
May 18, 2016 4:24 pm
Ryan Bushey, Digital Editor
The drug is expected to bring around $2.5 billion in annual sales by 2020. 
Subscribe to Drug Discovery & Development